Urothelial differentiation in chronically urine-deprived bladders of patients with end-stage renal disease

Kidney International

Volumn 68, Issue 3, 2005, Pages 1032-1040

  Stahlschmidt, Jens ^b   Varley, Claire L ^b   Toogood, Giles ^b   Selby, Peter J ^b   Southgate, Jennifer ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b NONE

Author keywords

Anuria; Bladder; Differentiation; PPAR; Prostaglandin; Urothelium

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ARACHIDONIC ACID; CELL NUCLEUS RECEPTOR; CYTOKERATIN 13; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 18; CYTOKERATIN 20; CYTOKERATIN 7; CYTOKERATIN 8; KI 67 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN J2; RETINOID X RECEPTOR; RETINOID X RECEPTOR ALPHA; RIBONUCLEASE; TROGLITAZONE; UROPLAKIN;

ADULT; ANURIA; ARACHIDONIC ACID METABOLISM; ARTICLE; BLADDER BIOPSY; BLADDER EPITHELIUM; BLADDER MUCOSA; CELL CULTURE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HEMODIALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; KIDNEY GRAFT; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UROTHELIUM;

ADULT; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; GENE EXPRESSION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; PPAR GAMMA; PROSTAGLANDIN D2; URINARY BLADDER; URINE; UROTHELIUM;

EID: 32644478044     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00495.x     Document Type: Article

References (37)

1. WU XR, LIN JH, WALZ T, et al: Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem 269:13716-13724, 1994
2. HU P, DENG FM, LIANG FX, et al: Ablation of uroplakin III gene results in small urothelial plaques, urothelial leakage, and vesicoureteral reflux. J Cell Biol 151:961-972, 2000
3. HU P, MEYERS S, LIANG FX, et al: Role of membrane proteins in permeability barrier function: Uroplakin ablation elevates urothelial permeability. Am J Physiol Renal Physiol 283:F1200-F1207, 2002
4. SOUTHGATE J, HUTTON KA, THOMAS DF, TREJDOSIEWICZ LK: Normal human urothelial cells in vitro: Proliferation and induction of stratification. Lab Invest 71:583-594, 1994
5. SOUTHGATE J, MASTERS JR, TREJDOSIEWICZ LK: Culture of human urothelium, in Culture of Epithelial Cells., edited by Freshney RI, Freshney MG, New York, J Wiley and Sons, Inc., 2002, pp 381-400
6. VARLEY CL, STAHLSCHMIDT J, SMITH B, et al: Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol 164:1789-1798, 2004
7. VARLEY CL, STAHLSCHMIDT J, LEE WC, et al: Role of PPAR {gamma} and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci 117:2029-2036, 2004
8. KLIEWER SA, UMESONO K, NOONAN DJ, et al: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771-774, 1992
9. ISSEMANN I, PRINCE RA, TUGWOOD JD, GREEN S: The retinoid X receptor enhances the function of the peroxisome proliferator activated receptor. Biochimie 75:251-256, 1993
10. GUAN YF, ZHANG YH, BREYER RM, et al: Expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1:330-339, 1999
11. KAWAKAMI S, ARAI G, HAYASHI T, et al: PPAR gamma ligands suppress proliferation of human urothelial basal cells in vitro. J Cell Physiol 191:310-319, 2002
12. JAIN S, PULIKURI S, ZHU Y, et al: Differential expression of the peroxisome proliferator-activated receptor gamma (PPAR gamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol 153:349-354, 1998
13. NAKASHIRO KI, HAYASHI Y, KITA A, et al: Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 159:591-597, 2001
14. 2 in human urine. J Biol Chem 263:16619-16625, 1988
15. REUTER EV: Urinary bladder, ureter, and renal pelvis, in Histology for Pathologists, edited by Sternberg SS, New York, Lippincott-Raven, 1997, pp 835-850
16. KAGEYAMA S, YOSHIKI T, ISONO T, et al: High expression of human uroplakin Ia in urinary bladder transitional cell carcinoma. Jpn J Cancer Res 93:523-531, 2002
17. ADACHI W, OKUBO K, KINOSHITA S: Human uroplakin Ib in ocular surface epithelium. Invest Ophthalmol Vis Sci 41:2900-2905, 2000
18. MANSEN A, GUARDIOLA-DIAZ H, RAFTER J, et al: Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonie mucosa. Biochem Biophys Res Commun 222:844-851, 1996
19. WINTZER HO, ZIPFEL I, SCHULTE-MONTING J, et al: Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67:421-428, 1991
20. LOBBAN ED, SMITH BA, HALL GD, et al: Uroplakin gene expression by normal and neoplastic human urothelium. Am J Pathol 153:1957-1967, 1998
21. SOUTHGATE J, HARNDEN P, TREJDOSIEWICZ LK: Cytokeratin expression patterns in normal and malignant urothelium: A review of the biological and diagnostic implications. Histol Histopathol 14:657-664, 1999
22. TONTONOZ P, HU E, SPIEGELMAN BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79:1147-1156, 1994
23. STRAKOVA N, EHRMANN J, DZUBAK P, et al: The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. J Pharmacol Exp Ther 309:1239-1247, 2004
24. CHEN GG, XU H, LEE JF, et al: 15-hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway. Int J Cancer 107:837-843, 2003
25. TSUJIE M, NAKAMORI S, OKAMI J, et al: Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. Exp Cell Res 289:143-151, 2003
26. OLSBURGH J, HARNDEN P, WEEKS R, et al: Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol 199:41-49, 2003
27. TU L, SUN TT, KREIBICH G: Specific heterodimer formation is a prerequisite for uroplakins to exit from the endoplasmic reticulum. Mol Biol Cell 13:4221-4230, 2002
28. OLSBURGH J, WEEKS R, SELBY P, SOUTHGATE J: Human uroplakin lb gene structure and promoter analysis. Biochim Biophys Acta 1576:163-170, 2002
29. BISHOP-BAILEY D: Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129:823-834, 2000
30. 2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813-819, 1995
31. FORMAN BM, TONTONOZ P, CHEN J, et al: 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83:803-812, 1995
32. THEVENON C, GUICHARDANT M, LAGARDE M: Gas chromatographic-mass spectrometric measurement of 15-deoxy-delta(12,14)-prostaglandin J(2), the peroxisome proliferator-activated receptor gamma ligand, in urine. Clin Chem 47:768-770, 2001
33. 2 transport across the plasma membrane of HeLa cells and Xenopus oocytes expressing the prostaglandin transporter "PGT." J Biol Chem 273:6689-6697, 1998
34. NOSJEAN O, BOUTIN JA: Natural ligands of PPAR gamma: Are prostaglandin J(2) derivatives really playing the part? Cell Signal 14:573-583, 2002
35. 2 synthase enzymes and PPAR gamma are co-expressed in mouse 3T3-L1 adipocytes and human tissues. Prostaglandins Other Lipid Mediat 70:267-284, 2003
36. MIWA S, FUSE H, HIRANO S, MASUDA S: Transitional cell carcinoma of the renal pelvis in a long-term hemodialysis patient with autosomal dominant polycystic kidney. Int J Urol 8:572-574, 2001
37. MOREY A, MARCO J, ALARCON A, et al: Bladder cancer in patients undergoing haemodialysis. Br J Urol 71:761, 1993